Decision support system for recommending EGFR-inhibiting drugs

我们中超过三分之一的人在有生之年会患上癌症。肺癌是最常见、最严重的癌症之一。在英国，每年约有4.65万人被诊断出患有这种疾病。更好的预防、更早的诊断和创新的新疗法意味着我们有一个现实的机会来大幅提高存活率。PRIME MD致力于改变游戏规则和颠覆性的技术，以检测有资格接受靶向治疗的患者。目前的方法是基于对活检样本进行的侵入性和昂贵的分析。这可以通过高级计算分析显著提高PreciousMD技术将人工智能能力与医学成像相结合，以制定超出人类专家所能提供的诊断方法。由于肺癌的高死亡率和巨大的公共成本负担，Precious MD从起点就将重点放在了这一类型的癌症上。PREARE MD团队由来自曼彻斯特大学、牛津大学和剑桥大学的知名数据科学家、图像处理专家、放射科医生、临床试验、人工智能专业人员、专家和商业/企业管理专家组成。我们打算让Precious MD技术成为临床实践和药物开发的常规部分，并大幅改善治疗癌症的方法。

More than one in three of us will get cancer in our lifetimes. Lung cancer is one of the most common and serious types of cancer. Around 46,500 people are diagnosed with the condition every year in the UK. Better prevention, earlier diagnosis and innovative new treatments mean we have a realistic opportunity to make major improvements in survival. Precious MD works on game-changing and disruptive technologies for detection of the patients who are eligible for receiving targeted therapy. Current approaches are based on invasive and expensive assays on samples taken from biopsy. This can be significantly improved by advanced computation analysisPreciousMD technology merge artificial intelligence capabilities with medical imaging to formulate diagnostic approach beyond what human experts can provide. Due to the high mortality rate and massive public cost burden of lung cancer, Precious MD has focused on this type of cancer at the starting point. Precious MD team is consist of a high profile data scientists, image processing specialists, radiologists, clinical trial, artificial intelligence professionals, specialists and commercial/business management experts from University of Manchester, Oxford and Cambridge. We intend for Precious MD technology to become a routine part of clinical practice and drug development and substantially improve the way of addressing cancer.